Dextrothyroxine (trade name Choloxin) is a dextrorotary isomer of thyroxine. It saw research as a cholesterol-lowering drug but was pulled due to cardiac side-effects. It increases hepatic lipase which in turn improves utilization of triglycerides and decreases levels of lipoprotein(a) in blood serum.
References
"Dextrothyroxine (Code C61719)". NCI Thesaurus. National Cancer Institute. 2011-11-14. Retrieved 2020-01-28. https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61719 ↩
Bantle JP, Hunninghake DB, Frantz ID, Kuba K, Mariash CN, Oppenheimer JH (September 1984). "Comparison of effectiveness of thyrotropin-suppressive doses of D- and L-thyroxine in treatment of hypercholesterolemia". The American Journal of Medicine. 77 (3): 475–81. doi:10.1016/0002-9343(84)90107-4. PMID 6475988. /wiki/Doi_(identifier) ↩
Bommer C, Werle E, Walter-Sack I, Keller C, Gehlen F, Wanner C, et al. (January 1998). "D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients". Journal of the American Society of Nephrology. 9 (1): 90–6. doi:10.1681/ASN.V9190. PMID 9440092. /wiki/Doi_(identifier) ↩